Loading
A phase 3 trial testing SHR-A1912 in diffuse large B-cell lymphoma, now recruiting.
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma is a phase 3 interventional study registered as NCT06929624, led by Suzhou Suncadia Biopharmaceuticals, and recruiting on the registry. Official title: A Phase 3, Open-label, Randomised Study of SHR-A1912 Combined With Rituximab + Gemcitabine + Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Planned enrolment is 280 participants (estimated). The study started in 2025-04-24 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.